



Corporate Press Release

July 2011

Norgine Environmental Policy Statement

The Norgine Group recognises the importance of efficiently utilising resources in developing, manufacturing and supplying its pharmaceutical products, minimising its impact on the environment, and encouraging initiatives within its workforce and with its partners to improve its environmental performance. The Norgine Business Code reflects its commitment to utilise all reasonable and prudent efforts to minimise the environmental impact of its activities, avoiding or minimising the use of hazardous substances and when practically feasible, promoting waste recycling and re-use.

Norgine policies and procedures are designed to comply with all country regulations and recommendations relating to environmental protection in force within the countries in which it carries out activities. Norgine's manufacturing sites are run strictly in accordance with the permitted activities.

Specific Norgine environmental endeavours implemented include:

- Recycling of materials at its manufacturing sites and at certain offices;
- Recycling of printer cartridges and mobile phones, disposal of dysfunctional computers, monitors and photocopiers through ISO 9001 certified service suppliers, and sale of obsolete IT equipment, the proceeds of which are donated to charity;
- Reducing the amounts of solvents utilised, waste generated and water used in the manufacturing process;
- Minimising outer packaging and the packaging weight of its pharmaceutical products;
- Instituting energy efficient lighting, including motion detector controlled lighting in certain offices;
- Adopting car fleet policies designed to reduce its CO2 emissions; and
- Evaluating the environmental policies of all goods and service providers as part of the Global Purchasing Supplier Selection Process.

Norgine is committed to progressively attaining internationally recognised environmental certification of all of its major sites through an ongoing Sustainable Environmental

Improvement Initiative. This Norgine initiative is aligned with European Union proposals designed to achieve sustainable carbon reduction targets.

Norgine encourages its suppliers and customers to support these environmental activities, to uphold similar environmental standards and to use products in an environmentally sensitive manner.

Norgine undertakes to review its policies and procedures and to engage in a program of continuous improvement of its environmental performance. Feedback is actively encouraged.

ENDS

About Norgine

Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine's net product sales were €258 million. The Company employs over 1,200 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a bowel cleansing preparation, KLEAN-PREP[®] for bowel preparation prior to colonoscopy, XIFAXAN[®] for the treatment of travellers diarrhoea and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.

Norgine Contact

Julie Hornby Winfield
Global Corporate Communications Manager
+44 (0) 1895 826600
jhornbywinfield@norgine.com